Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine and TMS for Fatigue in Multiple Sclerosis
NCT05809414Phase 3Recruiting
- Sponsor
- Hospital Clínico San Carlos
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amantadine in multiple sclerosis (MS) (4 arms), sponsored by Hospital Clínico San Carlos. Primary endpoint: Fatigue Severity at 6 weeks. Started Nov 2022; status: recruiting.
02
Drugs
amantadine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05809414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809414.